Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07248020
A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue (BCMRECRAD)
Sponsor: Chang Gung Memorial Hospital
Conditions
Chemoradiotherapy-Related Toxicity Locally Advanced Rectal Cancer Radiation Proctitis Radiation-Induced Enteritis Rectal Cancer
Interventions
Curcumin (BCM-95®)
Updated 1 time since 2025 Last updated: Nov 18, 2025 Started: Jan 1, 2026 Primary completion: Dec 31, 2028 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07248020, this PHASE2 trial focuses on Chemoradiotherapy-Related Toxicity and Locally Advanced Rectal Cancer and remains actively recruiting participants. Sponsored by Chang Gung Memorial Hospital, it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Chang Gung Memorial Hospital
Data source: Chang Gung Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .